5 result(s) displayed (1 - 5 of 5):
A restructuring Eli Lilly and Co. (NYSE:LLY), which faces patent losses on 80% of its key drugs by 2013, will report third-quarter earnings on Wednesday. A live Webcast of the conference call will be held from 9 a.m. to 10 a.m. Of first note, Lilly will take a 23...
Posted on October 19, 2009 10:45 AM
Eli Lilly & Co. (NYSE:LLY) is digesting its acquisitions of ImClone Systems Inc. for $6.5 billion and Monsanto Co.'s dairy cow hormone for $300 million, and it is preparing for tough times ahead when some major patents will face generic competition.Along with cutting 5,550 jobs, the company is undergoing...
Posted on September 14, 2009 12:46 PM
Agricultural biotech giant Monsanto Co. has been buying and selling all year. It just completed a $290 million acquisition, raised CEO Hugh Grant's compensation package by about 22% and reaffirmed predictions that gross profits would more than double from their 2007 levels to between $9.5 billion to $9.75 billion...
Posted on December 2, 2008 4:06 PM
Monsanto Co. wants to sell Posilac, its dairy hormone supplement business, and concentrate on its seed business. The company is looking to divest both the product and manufacturing facilities amid concern about potential side effects of bovine growth hormones, which are given to about 17% of U.S. cows, according to...
Posted on August 7, 2008 2:30 PM
In the past, plant biotechnologists concentrated on crops used primarily for animal feed. Lately, though, the genetic engineers have turned to creating crops for biofuels. Startups in the field have worked largely on behalf of agricultural chemical giants. Monsanto Co., Dow AgroSciences LLC, the DuPont Agriculture & Nutrition division of...
Posted on December 15, 2007 10:39 AM
Movable Type search results powered by Fast Search